News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Advertise
Talent Solutions
Post Jobs
Submit a Press Release
Submit an Event
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Advertise
Talent Solutions
Post Jobs
Submit a Press Release
Submit an Event
Search Query
Submit Search
News
Drug Development
Bayer AG’s Inhaler Drug Gets Thumbs Up in Test
May 20, 2008
|
1 min read
Twitter
LinkedIn
Facebook
Email
Print
FRANKFURT, May 20 (Reuters) - Bayer's (BAYG.DE: Quote, Profile, Research) experimental inhaler drug looked set to become a hit after a study of the device that patients use to inhale the antibiotic showed promising results, analysts said on Tuesday.
Twitter
LinkedIn
Facebook
Email
Print
Clinical research
Phase 2
Europe
Nektar Therapeutics
MORE ON THIS TOPIC
Layoffs
ADC Therapeutics lays off staff after 27 patient deaths mar Zynlonta readout
June 24, 2026
·
2 min read
·
Gabrielle Masson
Duchenne muscular dystrophy
REGENXBIO bets on FDA flexibility with filing plans for Duchenne gene therapy
June 24, 2026
·
2 min read
·
Gabrielle Masson
Deals
Novartis, Antares stars align in cancer deal that could top $1.9B
June 24, 2026
·
2 min read
·
Gabrielle Masson
Podcast
AbbVie keeps M&A rolling, FDA’s reversal train chugs along, BIO 2026 dispatch, more
June 24, 2026
·
1 min read
·
Jef Akst
